BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 апр 2023 07:00:36 Источник Nasdaq GlobeNewswire

BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

31 мар 2023 07:00:00 Источник Nasdaq GlobeNewswire

BioCryst Celebrates Bob Ingram’s Contributions to the Company’s Success

29 мар 2023 16:01:31 Источник Nasdaq GlobeNewswire

CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada

08 мар 2023 15:00:00 Источник Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 мар 2023 07:00:13 Источник Nasdaq GlobeNewswire

BioCryst Presents New Long-term and Real-world Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with ORLADEYO® (berotralstat)

24 фев 2023 07:00:00 Источник Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

22 фев 2023 07:00:04 Источник Nasdaq GlobeNewswire

BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones

21 фев 2023 07:00:23 Источник Nasdaq GlobeNewswire

BioCryst to Report Fourth Quarter 2022 Financial Results on February 21

07 фев 2023 07:00:16 Источник Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 фев 2023 07:00:30 Источник Nasdaq GlobeNewswire

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting

03 фев 2023 07:00:00 Источник Nasdaq GlobeNewswire

BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema

26 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire

BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern Europe

23 янв 2023 07:00:00 Источник Nasdaq GlobeNewswire

BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance

09 янв 2023 07:05:55 Источник Nasdaq GlobeNewswire

BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases

09 янв 2023 07:00:40 Источник Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 янв 2023 07:00:28 Источник Nasdaq GlobeNewswire

BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference

04 янв 2023 07:00:46 Источник Nasdaq GlobeNewswire

BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013

15 дек 2022 07:00:00 Источник Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 дек 2022 16:01:09 Источник Nasdaq GlobeNewswire

BioCryst to Present at JMP Securities Hematology & Oncology Summit

05 дек 2022 07:00:26 Источник Nasdaq GlobeNewswire